Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarendra Pegu

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Biorxiv : the Preprint Server for Biology|July 19, 2024
HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapyNicolas M S Galvez, Yi Cao, Adam D Nitido, et al.
Science Translational Medicine|August 19, 2021
Blocking α<sub>4</sub>β<sub>7</sub> integrin delays viral rebound in SHIV<sub>SF162P3</sub>-infected macaques treated with anti-HIV broadly neutralizing antibodiesInes Frank, Mariasole Cigoli, Muhammad S Arif, et al.
Nature Medicine|March 22, 2016
Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaquesAnn J Hessell, J Pablo Jaworski, Erin Epson, et al.
Immunity|September 5, 2021
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitopeLaura A VanBlargan, Lucas J Adams, Zhuoming Liu, et al.
The New England Journal of Medicine|July 7, 2021
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 VariantsVenkata-Viswanadh Edara, Benjamin A Pinsky, Mehul S Suthar, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2020
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibodyMangaiarkarasi Asokan, Joana Dias, Cuiping Liu, et al.
Immunity|February 26, 2026
HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized miceNicolas M S Galvez, Adam D Nitido, Seo Bin Yoo, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Scientific Reports|October 26, 2022
Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half lifeBaoshan Zhang, Deepika Gollapudi, Jason Gorman, et al.
Science Translational Medicine|September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challengeBoris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Biorxiv : the Preprint Server for Biology|July 19, 2024
HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapyNicolas M S Galvez, Yi Cao, Adam D Nitido, et al.
Science Translational Medicine|August 19, 2021
Blocking α<sub>4</sub>β<sub>7</sub> integrin delays viral rebound in SHIV<sub>SF162P3</sub>-infected macaques treated with anti-HIV broadly neutralizing antibodiesInes Frank, Mariasole Cigoli, Muhammad S Arif, et al.
Nature Medicine|March 22, 2016
Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaquesAnn J Hessell, J Pablo Jaworski, Erin Epson, et al.
Immunity|September 5, 2021
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitopeLaura A VanBlargan, Lucas J Adams, Zhuoming Liu, et al.
The New England Journal of Medicine|July 7, 2021
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 VariantsVenkata-Viswanadh Edara, Benjamin A Pinsky, Mehul S Suthar, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2020
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibodyMangaiarkarasi Asokan, Joana Dias, Cuiping Liu, et al.
Immunity|February 26, 2026
HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized miceNicolas M S Galvez, Adam D Nitido, Seo Bin Yoo, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Scientific Reports|October 26, 2022
Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half lifeBaoshan Zhang, Deepika Gollapudi, Jason Gorman, et al.
Science Translational Medicine|September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challengeBoris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
Pageof 9